Nakom (Carbidopa, Levodopa)

Carbidopa/Levodopa, the active ingredient in Nakom, is a dopamine precursor / decarboxylase inhibitor combination presented as an oral tablet formulation for oral use. It is indicated for the management of Parkinson's disease in adults. GNH USA supplies Nakom as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nakom, a dopamine precursor / decarboxylase inhibitor combination, is used in the treatment of Parkinsonian disorders. - Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor. - Early‑stage Parkinsonian syndrome: helps restore dopamine levels to reduce initial motor impairment. - Advanced Parkinson's disease with motor fluctuations: provides more consistent dopaminergic stimulation to lessen off‑periods.

Adverse reactions may occur with any dose of carbidopa/levodopa.

Common Side Effects: - Nausea: gastrointestinal upset often occurring after the first doses. - Dizziness: may be related to orthostatic blood pressure changes. - Headache: mild to moderate intensity. - Orthostatic hypotension: drop in blood pressure upon standing. - Insomnia: difficulty initiating or maintaining sleep. - Constipation: reduced bowel motility.

Serious or Rare Side Effects: - Severe hypotension: can lead to fainting or falls. - Hallucinations or psychosis: especially in older patients. - Dyskinesia: involuntary movements with long‑term use. - Neuroleptic malignant syndrome: rare but life‑threatening reaction. - Cardiac arrhythmias: irregular heart rhythms. - Severe depression or suicidal thoughts.

Patients should be monitored closely for safety concerns when using Nakom. - Dose titration: start with the lowest effective dose and adjust under medical supervision. - Cardiovascular monitoring: watch for orthostatic hypotension and falls. - Psychiatric evaluation: monitor for hallucinations, confusion, or mood changes. - Renal/hepatic function: assess before initiation and adjust if impairment is present. - Drug holidays: periodic assessment may be needed to reduce dyskinesia risk. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Carbidopa/levodopa can interact with several medication classes.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of severe hypertensive crisis. - MAO‑B inhibitors (e.g., selegiline) at high doses: may precipitate hypertension. - Anticholinergic agents: can mask peripheral side effects and alter efficacy.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: additive blood‑pressure‑lowering effect. - SSRIs or SNRIs: potential for serotonin syndrome. - Iron or calcium supplements: may reduce levodopa absorption; separate dosing by at least 2 hours.